Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Cancers|May 14, 2025
Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8<sup>+</sup> T Cells in Breast CancerPhilip B Emmerich, Tonela Qyli, Katherine A Johnson, et al.
Journal of Leukocyte Biology|March 4, 2017
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma nicheFotis Asimakopoulos, Chelsea Hope, Michael G Johnson, et al.
Cell Reports|August 17, 2022
Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironmentAthanasios Papadas, Gauri Deb, Alexander Cicala, et al.
Leukemia & Lymphoma|October 11, 2022
Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myelomaChristopher D'Angelo, Sailendharan Sudakaran, Fotis Asimakopoulos, et al.
Blood|July 9, 2020
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in miceZhi Wen, Adhithi Rajagopalan, Evan D Flietner, et al.
The Journal of Biological Chemistry|December 4, 2015
Loss of SIRT3 Provides Growth Advantage for B Cell MalignanciesWei Yu, Ryan A Denu, Kimberly A Krautkramer, et al.
British Journal of Haematology|May 16, 2012
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cellsJaehyup Kim, Ryan A Denu, Bridget A Dollar, et al.
Journal of Translational Medicine|November 12, 2022
Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancerIda Deichaite, Timothy J Sears, Leisa Sutton, et al.
Leukemia & Lymphoma|February 26, 2013
Macrophages in multiple myeloma: emerging concepts and therapeutic implicationsFotis Asimakopoulos, Jaehyup Kim, Ryan A Denu, et al.
Cancer Chemotherapy and Pharmacology|August 30, 2014
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology NetworkNatalie Callander, Stephanie Markovina, Jens Eickhoff, et al.
Pageof 4